Insider Transactions in Q2 2024 at Akebia Therapeutics, Inc. (AKBA)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Erik Ostrowski SVP, CFO, CBO & Treasurer |
BUY
Grant, award, or other acquisition
|
Direct |
350,000
+50.0%
|
-
|
|
Jun 06
2024
|
Cynthia Smith |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+19.33%
|
-
|
|
Jun 06
2024
|
Myles Wolf |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+23.5%
|
-
|
|
Jun 06
2024
|
Adrian Adams |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+15.4%
|
-
|
|
Jun 06
2024
|
Leanne M Zumwalt |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+28.93%
|
-
|
|
Jun 06
2024
|
Ron Frieson |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+28.93%
|
-
|
|
Jun 06
2024
|
Steven C Gilman |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+20.39%
|
-
|
|
Jun 06
2024
|
Michael W Rogers |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+19.23%
|
-
|
|
May 13
2024
|
Michel Dahan SVP, Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
34,840
-4.93%
|
$34,840
$1.26 P/Share
|
|
May 13
2024
|
Nicole R. Hadas SVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
12,016
-1.81%
|
$12,016
$1.26 P/Share
|